Pharmacologic Drug Detection and Self-Reported Adherence in the HPTN069/ACTG5305 Phase II PrEP Trial

By sjmartinez • August 1, 2024

Cooper SE, Zhang S, Haines D, Mayer KH, Amico KR, Landovitz RJ, Hendrix CW, Marzinke MA, Chege W, McCauley M, Gulick RM. Pharmacologic Drug Detection and Self-Reported Adherence in the HPTN069/ACTG5305 Phase II PrEP Trial. AIDS Behav. 2024 Jul 31. doi: 10.1007/s10461-024-04451-7. Epub ahead of print. PMID: 39083151.

Tags: Adherence, CASI, HIV prevention, Infectious Diseases, Maraviroc, PrEP, Publications, Tenofovir

Proteomic Immune Signatures of Severe HIV-Associated Tuberculosis in Sub-Saharan Africa: A Prospective, Multicenter Analysis From Uganda

Ross JE, Tomoiaga AS, Owor N, Lu X, Shinyale J, Kiyingi T, Asasira I, Eliku PJ, Nsubuga JB, Nsereko C, Nayiga I, Kyebambe S, Ochar[...]

“Someone could have told me”: a qualitative study on experiences with hysterectomy decision-making and regret in Mysore, India

Herbst de Cortina S, Karanam R, Pramathesh R, Begum F, Jaykrishna P, Srinivas V, Hariprasad R, Madhivanan P, Adsul P, Somaiya D. "Someone could have[...]

Bundibugyo virus glycoprotein seroreactivity following recombinant vesicular stomatitis virus-Zaire Ebola virus glycoprotein vaccination in outbreak-affected populations of the Democratic Republic of the Congo: a longitudinal cohort study

Halbrook M, Merritt S, Hoff NA, Mukadi P, Kompany JP, Musene K, Beya M, Kalengi H, Tambu M, Kelly JD, Ball AH, To A, MacGill[...]